Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology-Reference-Cited by-同舟云学术

Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology

Published:2012-07 Issue:7 Volume:23 Page:1730-1738
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Jalal S.I.,Riggs H.D.,Melnyk A.,Richards D.,Agarwala A.,Neubauer M.,Ansari R.,Govindan R.,Bruetman D.,Fisher W.,Breen T.,Johnson C.S.,Yu M.,Einhorn L.,Hanna N.

Funder

Sanofi-Aventis

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/7/1730/520581/mdr565.pdf

Reference43 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey;Morgensztern;J thorac Oncol,2010

3. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial;Dillman;J Natl Cancer Inst,1996